Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ribociclib (LEE011) Rollover Study for Continued Access

Phase 2

Recruiting

Conditions: Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

Interventions: Drug: LEE011

First Posted Date: 2016-10-17

Last Posted Date: 2024-04-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT02934568

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Dana Farber Cancer Institute Main Site, Boston, Massachusetts, United States

and more 3 locations

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: QCC374
Drug: Placebo Matching

First Posted Date: 2016-10-07

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT02927366

Locations: 🇬🇧
Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Phase 3

Completed

Conditions: Acute Myocardial Infarction

Interventions: Drug: LCZ696 (sacubitril/valsartan)
Drug: Ramipril
Drug: Placebo of ramipril
Drug: Placebo of LCZ696
Drug: Placebo of valsartan
Drug: Valsartan

First Posted Date: 2016-10-05

Last Posted Date: 2023-06-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5669

Registration Number: NCT02924727

Locations: 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

Phase 1

Completed

Conditions: cMET Dysegulation Advanced Solid Tumors

Interventions: Drug: INC280

First Posted Date: 2016-10-05

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT02925104

Locations: 🇺🇸
Indiana University Simon Cancer Center SC, Indianapolis, Indiana, United States
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Phase 3

Completed

Conditions: Corticosteroid Refractory Acute Graft vs Host Disease

Interventions: Drug: Ruxolitinib (RUX)
Drug: Best Available Therapy (BAT)

First Posted Date: 2016-09-23

Last Posted Date: 2023-02-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 310

Registration Number: NCT02913261

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Phase 2

Terminated

Conditions: Non-alcoholic Steatohepatitis NASH

Interventions: Drug: LMB763
Drug: Placebo

First Posted Date: 2016-09-23

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT02913105

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Phase 3

Completed

Conditions: Periodic Fevers Syndrome

Interventions: Biological: Canakinumab (AIN457)

First Posted Date: 2016-09-22

Last Posted Date: 2018-08-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT02911857

Locations: 🇯🇵
Novartis Investigative Site, Kyoto-city, Kyoto, Japan

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis

Completed

Conditions: RRMS
Multiple Sclerosis

Interventions: Other: Observational

First Posted Date: 2016-09-20

Last Posted Date: 2017-11-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 414

Registration Number: NCT02907281

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

Phase 3

Completed

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: LCZ696 (Sacubitril/Valsartan)
Drug: Placebo of LCZ696 (Sacubitril/Valsartan)
Drug: Placebo of Enalapril
Drug: Enalapril

First Posted Date: 2016-09-14

Last Posted Date: 2020-09-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 621

Registration Number: NCT02900378

Locations: 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1

Completed

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Interventions: Biological: PDR001
Drug: EGF816
Biological: CJM112
Biological: ACZ885
Drug: TMT212

First Posted Date: 2016-09-14

Last Posted Date: 2022-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 283

Registration Number: NCT02900664

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center SC-3, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy